Fresh analysis reveals that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who end traditional diet and exercise plans.
Findings released in a prominent health publication points out that while overweight individuals often shed substantial amounts of their total mass while using the jabs, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"Users using such medications need to be aware of the danger of quick weight regain when the medication ends," cautioned researcher Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight in about a year and a half.
Analyzing Approaches
The research, which reviewed dozens of studies involving thousands of participants, contrasted the results of the injectable medications with older methods.
Researchers emphasize that individuals who shed pounds through lifestyle changes alone usually see a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Quick Rebound
Nutrition scientists suggest the way of the drugs accounts for the accelerated regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of the hormone levels several times higher than normal could lead to the system to produce less of its endogenous hormone, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement means hunger is no longer kept in check, making overeating a significant risk."
A Chronic Disease?
Health authorities recommend the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians argue that, given the high risk of weight regain, the therapy is often ongoing.
This view is supported by pharmaceutical companies, who note that the results "highlight the long-term character of obesity," similar to managing diseases like hypertension.
Patient Accounts
Individuals who have discontinued the jabs report a sudden resurgence of cravings.
"I experienced a trigger flipping and I was suddenly starving," recalled an individual.
The struggle is exacerbated if users have not developed permanent dietary or behavioural changes during treatment.
Widespread Interest
Recent estimates suggest that millions of people in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Adoption is greater among women than men.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and long-term success hinges on integrated lifestyle support.
